Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS-PEDS fitusiran prophylaxis study in children with hemophilia A or B with inhibitors
2024-512501-76-00Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of fitusiran in hemophilia A and hemophilia B (HB), sponsored by Sanofi. Primary endpoint: Plasma antithrombin activity levels. Started Jul 2020; status: completed.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2024-512501-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512501-76-00.